Back to news

Regeneron gains as investors react to fresh clinical data and pipeline momentum

Investivoq PriceTracker

Regeneron Pharmaceuticals (REGN) is up 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied mainly to fresh positive clinical data for Pasatru, Regeneron’s treatment for fibrodysplasia ossificans progressiva, along with broader optimism around the company’s late-stage pipeline. Strength may also have been supported by recent price-target increases and growing attention on upcoming oncology updates and the next earnings report.

Details:

  • Regeneron said on October 12 that 84-week Phase 3 OPTIMA extension data for Pasatru showed zero new heterotopic ossification lesions in treated adults, compared with new lesions in the placebo group.
  • The same update showed fewer clinician-assessed flare-ups and a safety profile the company described as generally consistent with prior results, reinforcing confidence in the product after its recent U.S. approval.
  • Regeneron also recently highlighted multiple oncology presentations for ESMO 2026, including longer-term survival data for Libtayo in high-risk cutaneous squamous cell carcinoma, which may be helping sentiment around the pipeline.
  • This could also be because several analysts raised price targets in early October, suggesting Wall Street has been turning more constructive on Regeneron ahead of its October 30 third-quarter report.

    • Sources:

    Regeneron Pharmaceuticals, Benzinga, Stock Analysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $REGN Insider Trading Activity

    REGN Insider Trades

    $REGN insiders have traded $REGN stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.

    Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:

    • MARION MCCOURT (EVP Commercial) has made 0 purchases and 2 sales selling 2,346 shares for an estimated $2,002,458.
    • KATHRYN GUARINI has made 0 purchases and 2 sales selling 800 shares for an estimated $660,000.
    • HUDA Y ZOGHBI sold 800 shares for an estimated $640,000
    • ARTHUR F RYAN has made 0 purchases and 13 sales selling 300 shares for an estimated $200,553.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive REGN Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $REGN Hedge Fund Activity

    We have seen 590 institutional investors add shares of $REGN stock to their portfolio, and 684 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 3,774,199 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,353,364,044
    • INVESCO LTD. added 2,216,187 shares (+128.5%) to their portfolio in Q2 2026, for an estimated $1,381,881,241
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 846,306 shares (+inf%) to their portfolio in Q2 2026, for an estimated $527,705,643
    • FMR LLC removed 686,228 shares (-45.2%) from their portfolio in Q2 2026, for an estimated $427,890,607
    • PRICE T ROWE ASSOCIATES INC /MD/ removed 647,818 shares (-29.8%) from their portfolio in Q2 2026, for an estimated $403,940,435
    • CAPITAL WORLD INVESTORS removed 604,075 shares (-42.6%) from their portfolio in Q2 2026, for an estimated $376,664,925
    • WELLINGTON MANAGEMENT GROUP LLP removed 567,372 shares (-30.9%) from their portfolio in Q2 2026, for an estimated $353,779,136

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $REGN Congressional Stock Trading

    Members of Congress have traded $REGN stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:

    • REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 05/15.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $REGN Analyst Ratings

    Wall Street analysts have issued reports on $REGN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • HSBC issued a "Buy" rating on 07/06/2026
    • Barclays issued a "Overweight" rating on 04/30/2026
    • Truist Securities issued a "Buy" rating on 04/30/2026

    To track analyst ratings and price targets for $REGN, check out Investivoq's $REGN forecast page.

    $REGN Price Targets

    Multiple analysts have issued price targets for $REGN recently. We have seen 16 analysts offer price targets for $REGN in the last 6 months, with a median target of $759.5.

    Here are some recent targets:

    • Biren Amin from Piper Sandler set a target price of $854.0 on 07/09/2026
    • Matthew Harrison from Morgan Stanley set a target price of $730.0 on 07/08/2026
    • Gregory Renza from Truist Securities set a target price of $769.0 on 07/07/2026
    • Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
    • Brian Abrahams from RBC Capital set a target price of $696.0 on 07/07/2026
    • Carter Gould from Cantor Fitzgerald set a target price of $750.0 on 07/06/2026
    • Rajesh Kumar from HSBC set a target price of $880.0 on 07/06/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.